CSIMarket Company Name, Ticker, Suppliers, else..
 
Elevation Oncology inc   (NASDAQ: ELEV)
Other Ticker:  
 
 
Price: $0.3507 $0.00 1.241%
Day's High: $0.3516 Week Perf: -5.73 %
Day's Low: $ 0.34 30 Day Perf: 33.3 %
Volume (M): 366 52 Wk High: $ 4.48
Volume (M$): $ 129 52 Wk Avg: $1.28
Open: $0.35 52 Wk Low: $0.22



 Market Capitalization (Millions $) 20
 Shares Outstanding (Millions) 57
 Employees 84
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -44
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Elevation Oncology Inc
Elevation Oncology Inc. is a biopharmaceutical company that focuses on developing precision medicines for patients with genomically defined cancers. The company utilizes a biomarker-driven approach to identify and target the specific genetic alterations that drive cancer growth. Their aim is to improve patient outcomes by providing personalized therapies based on the specific genomic profiles of their tumors. Elevation Oncology's research and development efforts are centered around identifying new drug candidates and advancing them through clinical trials to ultimately bring novel treatments to cancer patients in need.


   Company Address: 101 Federal Street Boston 2110 MA
   Company Phone Number: 371-1125   Stock Exchange / Ticker: NASDAQ ELEV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BCRX        6.03% 
CCCC   -1.86%    
CRIS        20.67% 
CRSP   -2.96%    
EDIT   -4.97%    
RGNX        2.17% 
• View Complete Report
   



Elevation Oncology Inc

Elevation Oncology Inc Sees Success in Minimizing Losses Amidst Operational Challenges



During the ongoing earnings season from January to March 31, 2024, numerous companies across various sectors have reported their earnings. In the Biotechnology & Pharmaceuticals industry, Elevation Oncology Inc has announced its operating shortfall for the first quarter of 2024. Despite facing operational challenges, the company has managed to minimize losses in comparison to the same period last year. Additionally, Elevation Oncology Inc's stock has experienced a decline during the month of May, reflecting a negative sentiment among investors.
Earnings Report Analysis:
Elevation Oncology Inc has reported an operating shortfall of $-9.869 million for the first quarter of 2024. This figure is significantly lower than the $-17.059 million loss during the first quarter of 2023. The reduction in losses reflects improved operational decisions made by the company in the current period. It is important to note that these earnings highlight Elevation Oncology Inc's focus on expanding its business model.
Elevation Oncology Inc

Elevation Oncology Inc Shows Promising Growth in Fourth Quarter 2023 Financial Report

Elevation Oncology Inc (ELEV), a rising player in the Biotechnology & Pharmaceuticals sector, has recently released its financial numbers for the fourth quarter of 2023. The figures indicate a significant improvement compared to the same quarter in 2022, showcasing the company's potential for growth and success in the near future.
The operating deficit for the fourth quarter of 2023 has been reported at $-7.946 million, a remarkable reduction from the $-18.537 million deficit recorded in the same quarter of the previous year. This positive trend is a crucial indicator of the company's ability to execute its business strategy effectively and move forward towards its next phase of development.
Elevation Oncology Inc

Elevation Oncology Inc. Makes Strides Towards Success with Impressive Q3 Earnings

the Biotechnology & Pharmaceuticals sector continues to shape the financial landscape, lesser-known players are emerging with their respective numbers. Among them, Elevation Oncology Inc. (ELEV) recently reported a significant operating deficit of $-10.92 million for the third quarter of 2023. Although at first glance this may seem like discouraging news, it actually represents a positive shift from previous benchmarks.
In comparison to the Q3 of 2022, where the operating deficit stood at a staggering $-38.531 million, the reduction to $-10.92 million suggests progress and has garnered affirmation from industry analysts. This improvement is even more accentuated when considering that losses have decreased to $-10.636 million, down from $-38.837 million in the third quarter of 2022. These figures indicate a step forward for Elevation Oncology Inc., bolstering its position on the path to becoming a successful bellwether in the industry.
Elevation Oncology Inc

Elevation Oncology's Surprising Q2 2023 Performance: Operating Shortfall Reveals Gradual Improvement Despite Falling to $-20.113 Million in Biotech Sector



Elevation Oncology Inc, a renowned pharmaceutical company, recorded an unexpected operating shortfall during the April to June 30, 2023 reporting cycle. However, despite the shortfall, the company showcased improved financial performance compared to the same period last year. Investors had not anticipated any adjustments to the company's top-line figures during this reporting cycle.
During the aforementioned period, Elevation Oncology Inc's operating shortfall amounted to -$9.834 million. This noteworthy development indicates that the company managed to operate more economically compared to the corresponding interval in the previous year. In Q2 2022, the operating shortfall stood at -$20.113 million, signifying a significant reduction in losses.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com